GlassScriptPhysician profile
Marlo H Marcheleovich
NPI 1326240409
$4,717.40
in general payments reported to CMS, 2019-2025
22 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $523 · 2021: $549 · 2022: $393 · 2023: $1,228 · 2024: $788 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,078.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $799.88 | 2019-2024 | Farxiga, Breztri, Brilinta |
| Allergan, INC. | $378.40 | 2019-2020 | |
| Novo Nordisk INC | $338.57 | 2019-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $172.99 | 2023-2025 | Eliquis |
| Lilly USA, LLC | $142.45 | 2023-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $142.22 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $124.79 | 2021 | |
| Amgen INC. | $112.27 | 2019-2024 | Repatha, Otezla |
| Abbott Laboratories | $101.27 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $55.50 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.90 | 2019 | |
| Pfizer INC. | $34.36 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $27.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.26 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $27.18 | 2019 | |
| Viatris Specialty LLC | $20.07 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $19.78 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $19.33 | 2019 | |
| Amarin Pharma, INC. | $17.91 | 2019 | |
| Glaxosmithkline, LLC. | $13.42 | 2019 | |
| Astellas Pharma US INC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlo Marcheleovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.